CVE:ACST - Acasti Pharma Stock Price, Price Target & More

C$1.31 -0.06 (-4.38 %)
(As of 04/20/2018 04:00 PM ET)
Previous CloseC$1.31
Today's RangeC$1.27 - C$1.36
52-Week RangeC$1.07 - C$2.99
Volume118,600 shs
Average Volume55,473 shs
Market CapitalizationC$33.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46

About Acasti Pharma (CVE:ACST)

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCVE:ACST
CUSIPN/A
Phone+1-450-6864555

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-162.34%
Return on Assets-103.36%

Miscellaneous

EmployeesN/A
Outstanding Shares25,605,000

How to Become a New Pot Stock Millionaire

Acasti Pharma (CVE:ACST) Frequently Asked Questions

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

Who are some of Acasti Pharma's key competitors?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the folowing people:
  • Roderick Noel Carter, Executive Chairman of the Board
  • Janelle D'Alvise, President, Chief Executive Officer, Director
  • Linda Parinella O'Keefe, Chief Financial Officer
  • Pierre Lemieux Ph.D., Chief Operating Officer
  • Laurent Harvey, Vice President- Clinical and Non-Clinical Affairs
  • Jean-Daniel Belanger, Secretary, Director- Corporate Affairs
  • Jean-Marie Canan, Director (Age 61)

Has Acasti Pharma been receiving favorable news coverage?

Headlines about ACST stock have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acasti Pharma earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news articles about the company an impact score of 46.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately C$1.31.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of C$33.54 million.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.


MarketBeat Community Rating for Acasti Pharma (ACST)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acasti Pharma (CVE:ACST) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/21/2016 forward)

Earnings

Dividends

Acasti Pharma (CVE:ACST) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Acasti Pharma (CVE ACST) Insider Trading and Institutional Ownership History

Insider Trading History for Acasti Pharma (CVE:ACST)

Acasti Pharma (CVE ACST) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Jean-Daniel BélangerDirectorSell51,199C$2.41C$123,389.59
(Data available from 1/1/2013 forward)

Headlines

Acasti Pharma (CVE ACST) News Headlines

Source:

SEC Filings

Acasti Pharma (CVE:ACST) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Acasti Pharma (CVE ACST) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.